News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,112 Results
Type
Article (14251)
Company Profile (281)
Press Release (253580)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79533)
Career Advice (152)
Deals (13230)
Drug Delivery (35)
Drug Development (50462)
Employer Resources (31)
FDA (5724)
Job Trends (5133)
News (144437)
Policy (10032)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21674)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (100)
Approvals (5752)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (58)
Brain cancer (20)
Breast cancer (155)
Cancer (1479)
Cardiovascular disease (116)
Career advice (133)
Career pathing (2)
CAR-T (117)
Cell therapy (331)
Cervical cancer (8)
Clinical research (41087)
Collaboration (543)
Compensation (258)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (164)
Cystic fibrosis (76)
Data (1523)
Denatured (11)
Depression (30)
Diabetes (139)
Diagnostics (1300)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29835)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48612)
Executive appointments (464)
FDA (6422)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (254)
GLP-1 (366)
Government (1080)
Grass and pollen (2)
Guidances (22)
Healthcare (6594)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (114)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7274)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (209)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (101)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (53)
Medical device (2599)
Medtech (2600)
Mergers & acquisitions (6287)
Metabolic disorders (390)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1257)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (43)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (78)
Peanut (35)
People (25647)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14514)
Phase II (19111)
Phase III (12081)
Pipeline (808)
Policy (45)
Postmarket research (852)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8641)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (60)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1976)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (213)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (91)
Last 7 days (509)
Last 30 days (1508)
Last 365 days (19546)
2025 (6281)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23359)
2019 (16223)
2018 (11739)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10393)
2013 (7484)
2012 (7532)
2011 (7615)
2010 (7429)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17316)
Australia (2935)
California (3862)
Canada (1141)
China (360)
Colorado (149)
Connecticut (151)
Delaware (102)
Europe (37249)
Florida (465)
Georgia (116)
Idaho (16)
Illinois (232)
India (10)
Indiana (91)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (473)
Massachusetts (3082)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (967)
New Mexico (12)
New York (1045)
North Carolina (553)
North Dakota (5)
Northern California (1702)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (741)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1487)
Tennessee (25)
Texas (448)
United States (13267)
Utah (53)
Virginia (79)
Washington D.C. (30)
Washington State (351)
Wisconsin (15)
268,112 Results for "opsis therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, announced today that it has exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for the treatment of primary photoreceptor diseases, from FUJIFILM Cellular Dynamics and Opsis Therapeutics.
January 23, 2024
·
7 min read
Press Releases
Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
November 19, 2024
·
2 min read
Press Releases
RevOpsis Therapeutics Awarded $1.8M NEI SBIR Grant to Advance R&D for Groundbreaking Ophthalmic Therapies
October 15, 2024
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Business
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder
May 17, 2021
·
10 min read
Press Releases
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
·
13 min read
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
·
7 min read
Press Releases
Nutcracker Therapeutics to Showcase NMU-Symphony™ Platform for Personalized Cancer Therapeutics at Leading Industry Conferences
May 1, 2025
·
3 min read
Press Releases
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
April 21, 2025
·
3 min read
1 of 26,812
Next
